What are the main indications of Cabozantinib? Does it have a wide therapeutic range?

Cabozantinib was first widely used to treat advanced renal cell carcinoma (RCC), especially in patients who have progressed despite prior anti-angiogenic therapy. In multiple clinical studies, cabozantinib has shown excellent ability to prolong progression-free survival and overall survival, and has therefore been included in first- or second-line treatment options for renal cancer in many countries. Compared with traditional treatment, it is more stable in controlling tumor progression and is suitable for patients with intermediate and advanced renal cancer.

In addition to common kidney cancer, cabozantinib also plays an important role in the treatment of advanced medullary thyroid cancer (MTC). Cabozantinib is a key targeted therapy, especially for patients who are RET mutation negative or have no RET inhibitor options. Clinical data shows that it can significantly extend the disease control time of MTC patients, and it is currently one of the few targeted drugs available for this rare cancer.

In recent years, the indications of cabozantinib have been continuously expanded, and it has been approved for patients with advanced hepatocellular carcinoma (HCC) who have previously received sorafenib treatment. In the CELESTIAL phase III study, cabozantinib significantly extended patients' overall survival. For patients with liver cancer, cabozantinib provides a new treatment path, especially after immunotherapy fails, targeted therapy has become one of the new means of dependence.
In addition to the currently approved indications, cabozantinib has also been used in multiple clinical trials to study other solid tumors, including prostate cancer, breast cancer, non-small cell lung cancer, etc. Its multi-target inhibitory mechanism (including VEGFR, MET, AXL, etc.) gives it broad-spectrum anti-cancer potential. In the future, with in-depth research and the accumulation of more data, cabozantinib is expected to occupy a wider application space in the field of solid tumor treatment.
Reference: https://www.drugs.com/